WO2003072113A1 - Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound - Google Patents
Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound Download PDFInfo
- Publication number
- WO2003072113A1 WO2003072113A1 PCT/GB2003/000645 GB0300645W WO03072113A1 WO 2003072113 A1 WO2003072113 A1 WO 2003072113A1 GB 0300645 W GB0300645 W GB 0300645W WO 03072113 A1 WO03072113 A1 WO 03072113A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- closantel
- composition according
- compound
- polymeric species
- ivermectin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Definitions
- This invention relates to parasiticidal compositions, especially combination products for veterinary use, based on for example an avermectin or milbemycin together with another parasiticidal agent. Such combination products exhibit efficacy across a broader spectrum of parasites than is observed with the use of a single parasiticidal agent alone.
- Oral drenches, pastes, boluses, tablets, and granules for incorporating into feed mixes are known methods capable of being used by the animal husbandrymen, but other methods which are intended to avoid use of the gastrointestinal route are typically administered by qualified practitioners. Such other methods include use of aerosols, and parenteral drug compositions which are selectively prepared as solution or suspension or micronised powder formulations intended for subcutaneous, intracutaneous, and intramuscular injection according to the intended delivery regime. These last methods require special care in formulation to avoid irritation at the site of injection or possible adverse allergic or pyrogenic reactions.
- Injectable formulations are typically prepared using aqueous or non- aqueous (“solvent”) vehicles.
- solvent aqueous or non- aqueous
- the latter class may comprise physiologically tolerable alcohols, glycols, esters, a limited range of organic aromatic solvents, and vegetable oils and extracts or modified forms thereof.
- solvent aqueous or non- aqueous
- the skilled worker has to consider a number of issues including, solubility of the intended active ingredient(s), the affinity of the drug to certain vehicles, whether it will affect any essential auxiliaries, pH, stability over time, viscosity, and naturally the risk of any toxic effect upon the animal to be treated. Therefore, formulation of a parasiticide is a complex task.
- Traditional parasiticides include chemical agents such as the benzimidazoles, and carbamates, and plant extracts such as the pyrethroids, which tend to be used to combat ectoparasites such as ticks and mites.
- the avermectins are very potent antiparasitic agents which are useful against a broad spectrum of endoparasites and ectoparasites in mammals as well as having agricultural uses against various parasites found in and on crops and soil.
- the basic avermectin compounds are isolated from the fermentation broth of the soil micro-organism Streptomyces avermitilis and these compounds are described in US patent US 4 310519. Furthermore, derivatives of these basic avermectin compounds have been prepared by a variety of chemical means.
- avermectin group of compounds contain a 22, 23-double bond and others contain a disaccharide at the 13-position which consists of ⁇ -L- oleandrosyl- ⁇ -L-oleandrosyl group.
- One or both saccharide units can be removed forming a monosaccharide or an aglycone (where both saccharides are removed) as described in US patent US 4206205.
- the aglycone derivatives possess a hydroxy group at the 13 position which may be removed to form the 13-deoxy compound as described in the patents US 4 171 314 and US 4 173 571. Acylation of hydroxy groups on the avermectin compounds and derivatives can be carried out as described in US 4 201 861.
- milbemycin series of compounds disclosed in US 3 950 360, are structurally similar to the avermectin family in that they contain the sixteen membered macrocyclic ring. However, they do not contain the disaccharide sub- unit and there are differences in the substituent groups.
- Ivermectin disclosed in US 4 199 569, is prepared by the selective reduction of the 22, 23 double bond of the avermectin compounds.
- Ivermectin is a mixture of 22, 23-dihydro Avermectin B1a and B1 b in a ratio of at least 80:20.
- Ivermectin is an especially preferred active component in pesticidal compositions, and there is extensive literature on its activity, demonstrating its efficacy against internal and external parasites, and its ability to interfere in the life cycle of certain parasites.
- the erck Index (1996) cites several references including J.C.Chabala et al, J.Med.Chem.23, 1134 (1980); J.R.Egerton etal, Brit. Vet. J.136, 88 (1980); W.C.Campbell et al, Science 221 , 823-828 (1983) to mention but a few.
- ivermectin for the purposes of delivery in a variety of presentations, e.g. as an oral drench, pour-on, parenteral formulations, granules for adding to feed, and syringeable pastes, has proved highly challenging and numerous patents have been published on its use.
- Ivermectin exhibits a lipophilic character but it can be solvated in aqueous systems, and various patents describe special solvent systems for use in its formulation. Thus reference may be made at least to EP 0 045 655, and EP 0 146 414 for example.
- ivermectin is surprisingly effective, and has enjoyed a long period of commercial success, there remains a keen interest in exploiting ivermectin against a wider range of parasites and in overcoming tolerance by some parasites which demands higher amounts of ivermectin to be delivered. Taking into account the fact that a significant volume of use of ivermectin is in protecting and treating animals intended for human consumption, there are constraints on the residual amount of ivermectin in the carcass of such an animal. Therefore, high loadings of ivermectin, even if technically feasible, in a delivery system are not necessarily the optimum solution.
- Combination formulations are also desirable taking account of acquired tolerance or resistance in pests to prolonged usage of other more traditional parasiticidal agents. This phenomenon is well documented, e.g. in relation to worming compositions. Synergistic effects or complementary effects of combined parasiticidal agents have been observed as a route to combating the aforesaid tolerance problem. Synergistic anthelmintic compositions are discussed in WO 94/28887, which focuses on substituted mono- and bisphenols, salicylanilides, benzene sulphonamides, halogenated benzimidazoles, benzimidazoles, and benzimidazole carbamates.
- Closantel is described in US 4 005 218 and in the literature, e.g. J.Guerrero et al, J.Parasitol.68,616, (1983); H.Van den Bossche et al, Arch.lnt.Physiol.Biochim, 87, 851 (1979); H.J.Kane et al, Mol.Biochem.Parasitol.1 , 347(1980).
- Formulations of the pour-on and injectable type are discussed in WO 01/60380, which comprise use of a pyrrolidone solvent and a bridging solvent such as a xylene, optionally including a further solubility agent such as propylene glycol caprylic acids and esters or peanut oil.
- a pyrrolidone solvent and a bridging solvent such as a xylene, optionally including a further solubility agent such as propylene glycol caprylic acids and esters or peanut oil.
- a further solubility agent such as propylene glycol caprylic acids and esters or peanut oil.
- Salicylanilide derivatives such as closantel provide useful control over a range of parasites and are especially useful against liver fluke.
- the avermectin group of anti-parasitic compounds of which ivermectin is the best known example, provide complementary protection against many other parasites such as roundworms. Therefore, there are advantages to be gained if a combination of these drugs could be provided in a form that can be conveniently administered to livestock and which will provide effective control of parasitic infection.
- the established dose rate for injection of livestock is of the order of 200 ⁇ g/kg (ivermectin) and 2.5mg/kg (closantel).
- Ivermectin can be prepared in non-aqueous or low water content systems that are suitable for injection.
- Glycerol formal, propylene glycol, polyethylene glycol, pyrrolidone, and related solvents have been used in various formulations, singly or in combination.
- Patent publication WO 95/05812 discloses closantel and ivermectin solutions for injection using some of the solvents established as suitable for ivermectin (glycerol formal, polyethylene glycol, propylene glycol and water).
- the effectiveness of the formulations, in terms of bioavailability of the active parasiticidal agents, described in that patent application were not disclosed.
- Objects of the Invention Accordingly, it is an object of the present invention to provide improved veterinary pharmaceutical preparations.
- preparations which are suitable for administration by injection It is a further object of this invention to provide preparations which are suitable for administration by injection.
- a still further object of the invention is to provide a veterinary pharmaceutical product combining ivermectin and closantel in an effective formulation enabling enhanced bioavailability of closantel in excess of the observed prior art levels.
- PVP polyvinylpyrrolidone
- the invention enables the provision of injectable parasiticidal compositions, especially combination products, based on for example an avermectin or milbemycin together with another parasiticidal agent of the salicylanilide type with effective bioavailability of the parasiticidal agents.
- a parasiticidal composition comprises a first parasiticidal agent selected from amongst the avermectins and the milbemycins, together with another parasiticidal agent selected from the salicylanilides, in a physiologically tolerable solvent system rendering the said composition suitable for injection, characterised in that the composition comprises an amount of a polymeric species that is effective to provide blood plasma levels of the salicylanilide parasiticidal agent greater than about 20 ppm, over a period of treatment.
- the polymeric species is selected from a polyvinylpyrrolidone (PVP) or a polyoxypropylene/polyoxyethylene block copolymer, the former being especially preferred.
- PVP polyvinylpyrrolidone
- Polyoxypropylene/polyoxyethylene block copolymer the former being especially preferred.
- Polyvinylpyrrolidone is available in powder form of various molecular weights (M w circa 10,000 up to 55,000, and above: Aldrich Catalogue 2000-2001) for pharmaceutical use and is generally adopted as a dispersing and suspending agent (Merck Index).
- M w circa 10,000 up to 55,000 and above: Aldrich Catalogue 2000-2001
- Merck Index dispersing and suspending agent
- PVP is surprisingly found to be effective in the manufacture of a parasiticidal composition comprising closantel having long acting efficacy, such that the amount of PVP used enables the desired period of efficacy to be designed into the formulation to provide a controllable period of effective treatment whilst still permitting slaughter for human consumption of the treated animal if required having regard to the legally prescribed withdrawal period.
- a suitable solvent system comprises glycerol formal (GF), or a mixture of propylene glycol (PG) and GF, or a mixture of a polyethylene glycol (PEG) and GF.
- GF glycerol formal
- PG propylene glycol
- PEG polyethylene glycol
- a range of PEG solvents according to molecular weight is commercially available, and any of those, or others that may yet be made available, may be chosen for convenience provided that the PEG is presented or rendered available as a liquid during formulation.
- PEG 200 to 1500 are readily to hand from commercial sources, and thus can be used for the purposes herein, but PEG 200 to PEG 600 are usefully employed in this invention.
- a preferred solvent system consists of PEG 200 with GF.
- an avermectin preferably ivermectin
- a salicylanilide preferably closantel
- the potential ranges of the preferred parasiticidal agents useful in such formulations are: Ivermectin - from 0.1 to 10% w/v, preferably 1 to 5 % w/v;
- the quantity of polymeric species, especially polyvinylpyrrolidone, required to be effective depends on the desired salicylanilide activity of the mixture but typically at least 1 1 % PVP is required to permit the higher effective amounts of e.g. closantel desired to be achieved, and good results are demonstrated at levels of 15% or more.
- relative ratio of polymeric component to closantel it has been demonstrated that good bioavailability of closantel is achieved when a ratio of greater than 1 .44 :1 is established in the formulation.
- Performance Examples 1 to 7 describe the trials of prior art proposals in comparison with formulations according to the invention.
- Test Example 4 7.5 mg/kg closantel in a formulation of 0.5% ivermectin in glycerol formal with polyethylene glycol 200.
- the invention will be usefully applied in the field of veterinary medicine in particular for combating endoparasites and ectoparasites typically afflicting livestock such as bovines, equines, ovines and caprines.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003205887A AU2003205887B2 (en) | 2002-02-28 | 2003-02-12 | Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound |
APAP/P/2004/003142A AP1977A (en) | 2002-02-28 | 2003-02-12 | Long acting parasiticidal composition |
MXPA04007996A MXPA04007996A (en) | 2002-02-28 | 2003-02-12 | Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound. |
NZ534704A NZ534704A (en) | 2002-02-28 | 2003-02-12 | Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound |
BRPI0307974-0B1A BR0307974B1 (en) | 2002-02-28 | 2003-02-12 | “LONG-ACTING PARASITIC COMPOSITION CONTAINING ONE SALICYLANILIDE COMPOUND, ONE POLYMERIC SPECIES AND AT LEAST ONE OTHER ANTIPARASITIC COMPOUND” |
SI200330637T SI1478372T1 (en) | 2002-02-28 | 2003-02-12 | Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound |
DE60310377T DE60310377T2 (en) | 2002-02-28 | 2003-02-12 | A LONG-TERM, PARASITO-DESOLDERING PREPARATION CONTAINING A SALICYLANILIDE COMPOUND, A POLYMONIC COMPOUND, AND AT LEAST ONE MORE PARASITO-DESOLDERING COMPOUND |
DK03702765T DK1478372T3 (en) | 2002-02-28 | 2003-02-12 | Long-acting parasitic killing composition containing a salicylanilide compound, a polymer species and at least one other antiparasitic compound |
CA002476520A CA2476520C (en) | 2002-02-28 | 2003-02-12 | Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound |
JP2003570859A JP4480400B2 (en) | 2002-02-28 | 2003-02-12 | Persistent anthelmintic composition comprising a salicylanilide compound, a polymer component and at least one other antiparasitic compound |
US10/504,331 US9289380B2 (en) | 2002-02-28 | 2003-02-12 | Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound |
EP03702765A EP1478372B1 (en) | 2002-02-28 | 2003-02-12 | Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound |
ZA2004/06782A ZA200406782B (en) | 2002-02-28 | 2004-08-26 | Long acting parasiticidal composition containing a salicylanilide compound a polymeric species and at least one other anti-parasitic compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0204712A GB2386066A (en) | 2002-02-28 | 2002-02-28 | Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species |
GB0204712.4 | 2002-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003072113A1 true WO2003072113A1 (en) | 2003-09-04 |
Family
ID=9931978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2003/000645 WO2003072113A1 (en) | 2002-02-28 | 2003-02-12 | Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound |
Country Status (23)
Country | Link |
---|---|
US (1) | US9289380B2 (en) |
EP (1) | EP1478372B1 (en) |
JP (1) | JP4480400B2 (en) |
AP (1) | AP1977A (en) |
AR (1) | AR038852A1 (en) |
AT (1) | ATE347897T1 (en) |
AU (1) | AU2003205887B2 (en) |
BR (1) | BR0307974B1 (en) |
CA (1) | CA2476520C (en) |
CO (1) | CO5611154A2 (en) |
CR (1) | CR7429A (en) |
CY (1) | CY1107530T1 (en) |
DE (1) | DE60310377T2 (en) |
DK (1) | DK1478372T3 (en) |
EC (1) | ECSP045320A (en) |
ES (1) | ES2275076T3 (en) |
GB (1) | GB2386066A (en) |
MX (1) | MXPA04007996A (en) |
NZ (1) | NZ534704A (en) |
PT (1) | PT1478372E (en) |
SI (1) | SI1478372T1 (en) |
WO (1) | WO2003072113A1 (en) |
ZA (1) | ZA200406782B (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004089335A2 (en) * | 2003-03-31 | 2004-10-21 | Alza Corporation | Non-aqueous single phase vehicles and formulations utilizing such vehicles |
WO2006061214A1 (en) * | 2004-12-10 | 2006-06-15 | Bayer Healthcare Ag | Anthelmintic composition |
US7666444B2 (en) | 2004-02-02 | 2010-02-23 | Wyeth | Antiparasitic composition |
US8114437B2 (en) | 2005-02-03 | 2012-02-14 | Intarcia Therapeutics, Inc. | Solvent/polymer solutions as suspension vehicles |
WO2013182990A1 (en) | 2012-06-04 | 2013-12-12 | Virbac | Oxyclozanide-based veterinary composition for administration to the skin |
US9539200B2 (en) | 2005-02-03 | 2017-01-10 | Intarcia Therapeutics Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US9682127B2 (en) | 2005-02-03 | 2017-06-20 | Intarcia Therapeutics, Inc. | Osmotic delivery device comprising an insulinotropic peptide and uses thereof |
US9724293B2 (en) | 2003-11-17 | 2017-08-08 | Intarcia Therapeutics, Inc. | Methods of manufacturing viscous liquid pharmaceutical formulations |
WO2017157997A1 (en) * | 2016-03-16 | 2017-09-21 | Antibiotx Aps | Non-aqueous topical compositions comprising a halogenated salicylanilide |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US9949988B2 (en) | 2014-09-12 | 2018-04-24 | Antibiotx A/S | Antibacterial use of halogenated salicylanilides |
USD835783S1 (en) | 2016-06-02 | 2018-12-11 | Intarcia Therapeutics, Inc. | Implant placement guide |
US10159714B2 (en) | 2011-02-16 | 2018-12-25 | Intarcia Therapeutics, Inc. | Compositions, devices and methods of use thereof for the treatment of cancers |
US10231923B2 (en) | 2009-09-28 | 2019-03-19 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
US10463680B2 (en) | 2015-05-29 | 2019-11-05 | UNION therapeutics A/S | Halogenated salicylanilides for treating clostridium infections |
US10501517B2 (en) | 2016-05-16 | 2019-12-10 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
US10527170B2 (en) | 2006-08-09 | 2020-01-07 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies for use therein |
US10835580B2 (en) | 2017-01-03 | 2020-11-17 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
US11083796B2 (en) | 2005-07-26 | 2021-08-10 | Durect Corporation | Peroxide removal from drug delivery vehicle |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US11400019B2 (en) | 2020-01-13 | 2022-08-02 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002952597A0 (en) * | 2002-11-11 | 2002-11-28 | Schering-Plough Pty. Limited | Topical parasiticide formulations and methods of treatment |
MX2016004035A (en) * | 2013-09-30 | 2016-06-02 | Zoetis Services Llc | Long-acting spiro-isoxazoline formulations. |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4128632A (en) * | 1978-02-13 | 1978-12-05 | Merck & Co., Inc. | Solubilization of Rafoxanide |
EP0628302A2 (en) * | 1993-03-15 | 1994-12-14 | Colgate-Palmolive Company | Oral composition containing salicylanilide antibacterial agent |
WO1995005812A1 (en) * | 1993-08-24 | 1995-03-02 | Ashmont Holdings Limited | Anthelmintic formulations |
WO1995016447A1 (en) * | 1993-12-13 | 1995-06-22 | Michael Hilary Burke | Anthelmintic composition containing rafoxanide and fenbendazole |
FR2739778A1 (en) * | 1995-10-13 | 1997-04-18 | Virbac Lab | TOPICAL FORMULATION FOR TREATING LIVER LIVING DISEASE IN ANIMALS |
US6193989B1 (en) * | 1997-03-21 | 2001-02-27 | Biogenesis S.A. | Long acting injectable parasiticidal composition and the process for its preparation |
WO2002009764A1 (en) * | 2000-07-13 | 2002-02-07 | Ashmont Holdings Limited | Combination compositions |
WO2002094221A1 (en) * | 2001-05-18 | 2002-11-28 | Jupitar Pty Ltd | Emulsion and dispersion formulations and method |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3950360A (en) | 1972-06-08 | 1976-04-13 | Sankyo Company Limited | Antibiotic substances |
DE2263509C2 (en) | 1972-12-27 | 1981-12-24 | Rudolf Dr. 6380 Bad Homburg Kürner | deodorant |
US4005218A (en) * | 1975-03-18 | 1977-01-25 | Janssen Pharmaceutica N.V. | Antiparasitic salicylanilide derivatives |
SE434277B (en) * | 1976-04-19 | 1984-07-16 | Merck & Co Inc | SET TO MAKE NEW ANTIHELMINTICALLY EFFECTIVE ASSOCIATIONS BY CULTIVATING STREPTOMYCS AVERMITILIS |
US4199569A (en) * | 1977-10-03 | 1980-04-22 | Merck & Co., Inc. | Selective hydrogenation products of C-076 compounds and derivatives thereof |
US4206205A (en) * | 1977-10-03 | 1980-06-03 | Merck & Co., Inc. | Monosaccharide and aglycone derivatives of C-076 |
US4171314A (en) * | 1977-12-19 | 1979-10-16 | Merck & Co., Inc. | 13-Halo and 13-deoxy C-076 compounds |
US4173571A (en) * | 1977-12-19 | 1979-11-06 | Merck & Co., Inc. | 13-Halo and 13-deoxy derivatives of C-076 compounds |
NZ197796A (en) | 1980-08-04 | 1984-11-09 | Merck & Co Inc | Stabilised aqueous formulations containing ivermectin |
NZ210505A (en) | 1983-12-22 | 1988-06-30 | Merck & Co Inc | Parasiticidal compositions containing avermectin or milbemycin derivatives |
GB8727157D0 (en) * | 1987-11-19 | 1987-12-23 | Wellcome Found | Pharmaceutical formulations |
NZ223200A (en) * | 1988-01-15 | 1989-01-06 | Ancare Distributors | Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier |
US5273805A (en) * | 1991-08-05 | 1993-12-28 | Minnesota Mining And Manufacturing Company | Structured flexible carrier web with recess areas bearing a layer of silicone on predetermined surfaces |
NZ335166A (en) | 1999-04-14 | 2001-11-30 | Ashmont Holdings Ltd | Anthelmintic composition containing triclabendazole in at least one solvent |
PL174488B1 (en) | 1993-05-10 | 1998-08-31 | Merck & Co Inc | Preparations for fighting against animal parasites and method of obtaining such preparations |
NZ267366A (en) | 1993-06-15 | 1996-12-20 | Univ Australian | Controlling fasciola and other helminths using a synergistic composition of at least two anthelmintic active drugs each being selected from a different class of drug |
US5773422A (en) * | 1996-01-29 | 1998-06-30 | Komer; Gene | Avermectin formulation |
US6340672B1 (en) | 2000-02-16 | 2002-01-22 | Phoenix Scientific, Inc. | Parasiticidal formulation and a method of making this formulation |
-
2002
- 2002-02-28 GB GB0204712A patent/GB2386066A/en not_active Withdrawn
-
2003
- 2003-02-12 AP APAP/P/2004/003142A patent/AP1977A/en active
- 2003-02-12 CA CA002476520A patent/CA2476520C/en not_active Expired - Lifetime
- 2003-02-12 ES ES03702765T patent/ES2275076T3/en not_active Expired - Lifetime
- 2003-02-12 PT PT03702765T patent/PT1478372E/en unknown
- 2003-02-12 US US10/504,331 patent/US9289380B2/en active Active
- 2003-02-12 JP JP2003570859A patent/JP4480400B2/en not_active Expired - Lifetime
- 2003-02-12 EP EP03702765A patent/EP1478372B1/en not_active Expired - Lifetime
- 2003-02-12 WO PCT/GB2003/000645 patent/WO2003072113A1/en active IP Right Grant
- 2003-02-12 NZ NZ534704A patent/NZ534704A/en not_active IP Right Cessation
- 2003-02-12 BR BRPI0307974-0B1A patent/BR0307974B1/en not_active IP Right Cessation
- 2003-02-12 SI SI200330637T patent/SI1478372T1/en unknown
- 2003-02-12 DE DE60310377T patent/DE60310377T2/en not_active Expired - Lifetime
- 2003-02-12 AT AT03702765T patent/ATE347897T1/en active
- 2003-02-12 MX MXPA04007996A patent/MXPA04007996A/en active IP Right Grant
- 2003-02-12 AU AU2003205887A patent/AU2003205887B2/en not_active Expired
- 2003-02-12 DK DK03702765T patent/DK1478372T3/en active
- 2003-02-27 AR ARP030100640A patent/AR038852A1/en not_active Application Discontinuation
-
2004
- 2004-08-24 CR CR7429A patent/CR7429A/en unknown
- 2004-08-26 ZA ZA2004/06782A patent/ZA200406782B/en unknown
- 2004-09-14 CO CO04091274A patent/CO5611154A2/en not_active Application Discontinuation
- 2004-09-28 EC EC2004005320A patent/ECSP045320A/en unknown
-
2007
- 2007-01-10 CY CY20071100037T patent/CY1107530T1/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4128632A (en) * | 1978-02-13 | 1978-12-05 | Merck & Co., Inc. | Solubilization of Rafoxanide |
EP0628302A2 (en) * | 1993-03-15 | 1994-12-14 | Colgate-Palmolive Company | Oral composition containing salicylanilide antibacterial agent |
WO1995005812A1 (en) * | 1993-08-24 | 1995-03-02 | Ashmont Holdings Limited | Anthelmintic formulations |
WO1995016447A1 (en) * | 1993-12-13 | 1995-06-22 | Michael Hilary Burke | Anthelmintic composition containing rafoxanide and fenbendazole |
FR2739778A1 (en) * | 1995-10-13 | 1997-04-18 | Virbac Lab | TOPICAL FORMULATION FOR TREATING LIVER LIVING DISEASE IN ANIMALS |
US6193989B1 (en) * | 1997-03-21 | 2001-02-27 | Biogenesis S.A. | Long acting injectable parasiticidal composition and the process for its preparation |
WO2002009764A1 (en) * | 2000-07-13 | 2002-02-07 | Ashmont Holdings Limited | Combination compositions |
WO2002094221A1 (en) * | 2001-05-18 | 2002-11-28 | Jupitar Pty Ltd | Emulsion and dispersion formulations and method |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004089335A3 (en) * | 2003-03-31 | 2005-02-10 | Alza Corp | Non-aqueous single phase vehicles and formulations utilizing such vehicles |
WO2004089335A2 (en) * | 2003-03-31 | 2004-10-21 | Alza Corporation | Non-aqueous single phase vehicles and formulations utilizing such vehicles |
US8496943B2 (en) | 2003-03-31 | 2013-07-30 | Durect Corporation | Non-aqueous single phase vehicles and formulations utilizing such vehicles |
US9724293B2 (en) | 2003-11-17 | 2017-08-08 | Intarcia Therapeutics, Inc. | Methods of manufacturing viscous liquid pharmaceutical formulations |
US7666444B2 (en) | 2004-02-02 | 2010-02-23 | Wyeth | Antiparasitic composition |
WO2006061214A1 (en) * | 2004-12-10 | 2006-06-15 | Bayer Healthcare Ag | Anthelmintic composition |
US10363287B2 (en) | 2005-02-03 | 2019-07-30 | Intarcia Therapeutics, Inc. | Method of manufacturing an osmotic delivery device |
US8114437B2 (en) | 2005-02-03 | 2012-02-14 | Intarcia Therapeutics, Inc. | Solvent/polymer solutions as suspension vehicles |
US9526763B2 (en) | 2005-02-03 | 2016-12-27 | Intarcia Therapeutics Inc. | Solvent/polymer solutions as suspension vehicles |
US9539200B2 (en) | 2005-02-03 | 2017-01-10 | Intarcia Therapeutics Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US9682127B2 (en) | 2005-02-03 | 2017-06-20 | Intarcia Therapeutics, Inc. | Osmotic delivery device comprising an insulinotropic peptide and uses thereof |
US9095553B2 (en) | 2005-02-03 | 2015-08-04 | Intarcia Therapeutics Inc. | Solvent/polymer solutions as suspension vehicles |
US11083796B2 (en) | 2005-07-26 | 2021-08-10 | Durect Corporation | Peroxide removal from drug delivery vehicle |
US10527170B2 (en) | 2006-08-09 | 2020-01-07 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies for use therein |
US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US10441528B2 (en) | 2008-02-13 | 2019-10-15 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US10869830B2 (en) | 2009-09-28 | 2020-12-22 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
US10231923B2 (en) | 2009-09-28 | 2019-03-19 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
US10159714B2 (en) | 2011-02-16 | 2018-12-25 | Intarcia Therapeutics, Inc. | Compositions, devices and methods of use thereof for the treatment of cancers |
WO2013182990A1 (en) | 2012-06-04 | 2013-12-12 | Virbac | Oxyclozanide-based veterinary composition for administration to the skin |
US10758553B2 (en) | 2014-09-12 | 2020-09-01 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
US11285164B2 (en) | 2014-09-12 | 2022-03-29 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
US11324761B2 (en) | 2014-09-12 | 2022-05-10 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
US9949988B2 (en) | 2014-09-12 | 2018-04-24 | Antibiotx A/S | Antibacterial use of halogenated salicylanilides |
US11331327B2 (en) | 2014-09-12 | 2022-05-17 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10583080B2 (en) | 2014-09-30 | 2020-03-10 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10463680B2 (en) | 2015-05-29 | 2019-11-05 | UNION therapeutics A/S | Halogenated salicylanilides for treating clostridium infections |
US10857164B2 (en) | 2015-05-29 | 2020-12-08 | UNION therapeutics A/S | Halogenated salicylanilides for treating Clostridium infections |
US11529361B2 (en) | 2015-05-29 | 2022-12-20 | UNION therapeutics A/S | Halogenated salicylanilides for treating Clostridium infections |
US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
CN108883309A (en) * | 2016-03-16 | 2018-11-23 | 德克抗生素股份公司 | Non-aqueous topical composition comprising halogenated salicylanilide |
CN108883309B (en) * | 2016-03-16 | 2021-08-17 | 联合治疗股份公司 | Non-aqueous topical compositions comprising halogenated salicylanilides |
WO2017157997A1 (en) * | 2016-03-16 | 2017-09-21 | Antibiotx Aps | Non-aqueous topical compositions comprising a halogenated salicylanilide |
US10501517B2 (en) | 2016-05-16 | 2019-12-10 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
US11840559B2 (en) | 2016-05-16 | 2023-12-12 | I2O Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
US11214607B2 (en) | 2016-05-16 | 2022-01-04 | Intarcia Therapeutics Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD835783S1 (en) | 2016-06-02 | 2018-12-11 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD962433S1 (en) | 2016-06-02 | 2022-08-30 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD912249S1 (en) | 2016-06-02 | 2021-03-02 | Intarcia Therapeutics, Inc. | Implant removal tool |
US10835580B2 (en) | 2017-01-03 | 2020-11-17 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
US11654183B2 (en) | 2017-01-03 | 2023-05-23 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of exenatide and co-administration of a drug |
US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
US11400019B2 (en) | 2020-01-13 | 2022-08-02 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
US11771624B2 (en) | 2020-01-13 | 2023-10-03 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
Also Published As
Publication number | Publication date |
---|---|
CA2476520A1 (en) | 2003-09-04 |
JP2005525355A (en) | 2005-08-25 |
AP1977A (en) | 2009-03-19 |
PT1478372E (en) | 2007-01-31 |
AU2003205887B2 (en) | 2007-02-15 |
AR038852A1 (en) | 2005-01-26 |
BR0307974A (en) | 2004-12-21 |
ES2275076T3 (en) | 2007-06-01 |
EP1478372A1 (en) | 2004-11-24 |
CA2476520C (en) | 2009-08-11 |
DK1478372T3 (en) | 2007-04-10 |
ATE347897T1 (en) | 2007-01-15 |
DE60310377D1 (en) | 2007-01-25 |
JP4480400B2 (en) | 2010-06-16 |
CO5611154A2 (en) | 2006-02-28 |
ECSP045320A (en) | 2004-11-26 |
MXPA04007996A (en) | 2004-11-26 |
AP2004003142A0 (en) | 2004-09-30 |
EP1478372B1 (en) | 2006-12-13 |
DE60310377T2 (en) | 2007-10-31 |
SI1478372T1 (en) | 2007-04-30 |
CR7429A (en) | 2006-02-06 |
GB0204712D0 (en) | 2002-04-17 |
NZ534704A (en) | 2007-02-23 |
BR0307974B1 (en) | 2014-10-21 |
ZA200406782B (en) | 2005-07-27 |
US20050118221A1 (en) | 2005-06-02 |
US9289380B2 (en) | 2016-03-22 |
AU2003205887A1 (en) | 2003-09-09 |
GB2386066A (en) | 2003-09-10 |
CY1107530T1 (en) | 2013-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2476520C (en) | Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound | |
US8993546B2 (en) | Parasiticidal composition | |
AU2008282388A1 (en) | Endoparasiticidal topical compositions | |
AU2006322120B2 (en) | Benzimidazole non-aqueous compositions | |
WO2003072112A1 (en) | 'long'-'acting' injectable parasiticidal composition | |
EP1259244B1 (en) | Veterinary compositions for the treatment of parasitic diseases | |
NZ537760A (en) | Worming formulations comprising a macrocyclic lactone and piperonyl butoxide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 534704 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003205887 Country of ref document: AU Ref document number: 2476520 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/007996 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/06782 Country of ref document: ZA Ref document number: 200406782 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003570859 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003702765 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003702765 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10504331 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003702765 Country of ref document: EP |